Qiagen NV

QIA: XETR (DEU)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€78.00VqlkLnwwppjh

Qiagen Delivers Decent Q4 Despite Declining COVID-19-Related Sales; Shares Fairly Valued

No-moat Qiagen turned in better-than-anticipated fourth-quarter results that allowed it to mildly exceed our revenue and adjusted EPS expectations in 2022. The company's 2023 guidance also looks in line with our expectations. To reflect recently generated cash flow, we have mildly increased our U.S.-denominated fair value estimate, but with the recent strengthening of the euro relative to the U.S. dollar, we have slightly trimmed our EUR-denominated fair value estimate. Even after those changes, Qiagen shares still appear fairly valued.

Sponsor Center